GAM Holding AG reduced its stake in shares of Boston Scientific Corp. (NYSE:BSX) by 9.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 201,969 shares of the company’s stock after selling 20,062 shares during the period. GAM Holding AG’s holdings in Boston Scientific Corp. were worth $4,807,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Trust Co. of Vermont boosted its stake in Boston Scientific Corp. by 2,298.3% in the third quarter. Trust Co. of Vermont now owns 4,221 shares of the company’s stock valued at $100,000 after buying an additional 4,045 shares during the period. Synovus Financial Corp bought a new stake in Boston Scientific Corp. during the third quarter valued at about $102,000. Bronfman E.L. Rothschild L.P. boosted its stake in Boston Scientific Corp. by 1.5% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 4,511 shares of the company’s stock valued at $107,000 after buying an additional 66 shares during the period. Global X Management Co. LLC boosted its stake in Boston Scientific Corp. by 91.8% in the second quarter. Global X Management Co. LLC now owns 4,683 shares of the company’s stock valued at $109,000 after buying an additional 2,242 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in Boston Scientific Corp. by 1.7% in the second quarter. Quadrant Capital Group LLC now owns 4,844 shares of the company’s stock valued at $105,000 after buying an additional 83 shares during the period. 89.96% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Boston Scientific Corp. (NYSE:BSX)

Boston Scientific Corp. (NYSE:BSX) traded down 1.49% during trading on Wednesday, reaching $20.46. 12,496,799 shares of the company’s stock traded hands. Boston Scientific Corp. has a one year low of $15.67 and a one year high of $24.79. The stock has a market cap of $27.86 billion, a P/E ratio of 386.04 and a beta of 1.15. The firm’s 50 day moving average price is $22.04 and its 200-day moving average price is $23.09.

Boston Scientific Corp. (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 26th. The company reported $0.27 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.27. The company had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $2.07 billion. Boston Scientific Corp. had a net margin of 0.99% and a return on equity of 23.25%. Boston Scientific Corp.’s revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.24 EPS. On average, equities analysts anticipate that Boston Scientific Corp. will post $1.10 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/30/gam-holding-ag-decreases-position-in-boston-scientific-corp-bsx.html.

BSX has been the subject of several recent research reports. TheStreet upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating in a report on Wednesday, October 26th. Zacks Investment Research lowered shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Monday, October 31st. Citigroup Inc. boosted their price target on shares of Boston Scientific Corp. from $28.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, October 6th. Royal Bank Of Canada restated an “outperform” rating and issued a $28.00 price target on shares of Boston Scientific Corp. in a report on Friday, October 14th. Finally, Argus upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and boosted their price target for the company from $23.82 to $33.00 in a report on Thursday, September 1st. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $25.70.

Boston Scientific Corp. Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Receive News & Stock Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related stocks with our FREE daily email newsletter.